

NORDIC WEBINAR

Measurable residual disease during the course of AML

Tuesday 10th of October 2023

15:30 to 17:30 CEST

Measurable residual disease (MRD) is an important prognostic factor during the course of AML, but how do we use it in clinical practice and how can MRD guide treatment choices and be informative for risk-adapted therapy and follow-up?

- 15:30-15:35** **Welcome and introduction to the webinar,**
*By **Daniel Tuyet Kristensen**, NAMLG EWG member, Aalborg University Hospital, DK*
- 15:35-16:00** **MRD pre-transplant**
*By **Laura W. Dillon**, NHLBI, Bethesda, US*
- 16:00-16:25** **MRD post intensive Induction**
*By **Richard Dillon**, Kings College, London, UK*
- 16:25-16:45** **MRD-adapted therapy in intermediate risk AML, update from the AML1310 trial (GIMEMA)**
*By **Raffaele Palmieri**, Rome University, Italy*
- 16:45-17:25** **Nordic practices and panel discussion**
*By **Hans Beier Ommen**, Aarhus University Hospital, Denmark
Linda Fogelstrand, Sahlgrenska University Hospital and Department of Laboratory Medicine, University of Gothenburg*
- Panelists – MRD-guided therapy in the Nordic countries**
***Hans Beier Ommen**, Aarhus University Hospital, Denmark
Laura W. Dillon, NHLBI, Bethesda, US
Linda Fogelstrand, Sahlgrenska University Hospital and, University of Gothenburg, Sweden
Raffaele Palmieri, Rome University, Italy
Richard Dillon, Kings College, London, UK*
- 17:25-17:30:** **Closing remarks, NAMLG EWG member.**

Registration

You can sign up for the webinar [here](#).

Participation is free of charge for doctors and other healthcare profession.

Medicinske Tidsskrifter has applied for and obtained sponsorship support to complete the webinar from Jazz Pharmaceutical